264208-66-4

Basic information

• Product Name: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate
• Synonyms: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate;Ethyl 2-amino-5-methoxy-4-((1-methylpiperidin-4-yl)methoxy)benzoate;4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate
• CAS NO: 264208-66-4
• Molecular Formula: C₁₇H₂₆N₂O₄
• Molecular Weight: 322.39934
• Mol File: 264208-66-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 457.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.120±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.05±0.10(Predicted)
• CAS DataBase Reference: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate(264208-66-4)
• EPA Substance Registry System: ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate(264208-66-4)

Safety Data

• Hazardous Substances Data: 264208-66-4(Hazardous Substances Data)

Usage

General Description

"Ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate" is a chemical compound with a specific molecular structure, incorporating elements such as carbon, hydrogen, nitrogen, and oxygen. Its structural components contribute to its chemical properties and behavior. ethyl 4-((1-Methylpiperidin-4-yl)Methoxy)-2-aMino-5-Methoxybenzoate belongs to the class of organic compounds known as benzoic acid esters, which are characterized by an ester derivative of benzoic acid. Its potential applications could be in various fields including science and industry, possibly involved in the production of certain types of synthetic materials, pharmaceuticals or in research and development. However, specific details about its properties, applications, and safety measures are not readily available and may require further research or specialist knowledge.

Upstream product

• 264208-63-1 ethyl 3-methoxy-4-(1-methylpiperidin-4-ylmethoxy)-6-nitrobenzoate 

Downstream Products

• 264208-69-7 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3,4-dihydroxyquinazolin-4-one 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS

The invention relates to quinazoline derivatives of the formula I:- wherein: m is an integer from 1 to 3; R 1 represents halogeno or C 1-3 alkyl; X 1 represents -O-; R 2 is selected from one of the following three groups: 1) C 1-5 alkylR 3 (wherein R 3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 alkoxy; 2) C 2-5 alkenylR 3 (wherein R 3 is as defined hereinbefore); 3) C 2-5 alkynylR 3 (wherein R 3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Quinazoline derivatives

The invention concerns quinazoline derivatives of Formula (I) wherein Q1includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1includes a direct bond and O and Q3includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2and R3is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.